Novo Nordisk and the FDA warned that nearly 130,000 vials of long-acting Levemir insulin were stolen and could have been mishandled, making them potentially dangerous for patients. The agency said it received one report of adverse events linked to the stolen lots, identified as XZF0036, XZF0037 and XZF0038.

Related Summaries